Apelin Deficiency Accelerates the Progression of Amyotrophic Lateral Sclerosis by Kasai, Atsushi et al.
Apelin Deficiency Accelerates the Progression of
Amyotrophic Lateral Sclerosis
Atsushi Kasai
1,3*, Toshihiko Kinjo
1, Rie Ishihara
1, Ikumi Sakai
1, Yuki Ishimaru
1, Yasuhiro Yoshioka
1,
Akiko Yamamuro
1, Kumiko Ishige
2, Yoshihisa Ito
2, Sadaaki Maeda
1
1Department of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan, 2Laboratory of Pharmacology, Department of
Pharmacy, School of Pharmacy, Nihon University. Funabashi, Chiba, Japan, 3Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University
of California Los Angeles, Los Angeles, California, United States of America
Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the selective loss of motor neurons.
Recent studies have implicated that chronic hypoxia and insufficient vascular endothelial growth factor (VEGF)-dependent
neuroprotection may lead to the degeneration of motor neurons in ALS. Expression of apelin, an endogenous ligand for the
G protein-coupled receptor APJ, is regulated by hypoxia. In addition, recent reports suggest that apelin protects neurons
against glutamate-induced excitotoxicity. Here, we examined whether apelin is an endogenous neuroprotective factor
using SOD1
G93A mouse model of ALS. In mouse CNS tissues, the highest expressions of both apelin and APJ mRNAs were
detected in spinal cord. APJ immunoreactivity was observed in neuronal cell bodies located in gray matter of spinal cord.
Although apelin mRNA expression in the spinal cord of wild-type mice was not changed from 4 to 18 weeks age, that of
SOD1
G93A mice was reduced along with the paralytic phenotype. In addition, double mutant apelin-deficient and SOD1
G93A
displayed the disease phenotypes earlier than SOD1
G93A littermates. Immunohistochemical observation revealed that the
number of motor neurons was decreased and microglia were activated in the spinal cord of the double mutant mice,
indicating that apelin deficiency pathologically accelerated the progression of ALS. Furthermore, we showed that apelin
enhanced the protective effect of VEGF on H2O2-induced neuronal death in primary neurons. These results suggest that
apelin/APJ system in the spinal cord has a neuroprotective effect against the pathogenesis of ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS), the most common adult-
onset motor neuron disease, is caused by a selective loss of motor
neurons leading to progressive paralysis of muscles and ultimately
death [1]. Approximately 10% of ALS cases is familial, of which
20% are associated with dominant mutations in the gene encoding
the human Cu
2+/Zn
2+ superoxide dismutase-1 (SOD1) [2].
Transgenic animals overexpressing mutant SOD1 develop pro-
gressive motor neuron disease that resembles the clinical and
pathological features of human familial ALS [3]. Although the
precise pathogenesis of ALS remains unclear, studies using these
animal models have proposed several hypotheses to explain motor
neuron degeneration, including glutamate-induced excitotoxicity
[4] and oxidative damage [1].
Recently, chronic hypoxia and insufficient vascular endothelial
growth factor (VEGF)-dependent neuroprotection has been linked
to the degeneration of motor neurons in ALS. Mice with deletion
of the hypoxia-response element in the VEGF promoter region
(VEGF
d/d) develop spinal hypoperfusion and adult-onset progres-
sive motor neuron degeneration [5]. Prior to motor neuron
degeneration, SOD1 mutants exhibit disruption of the blood-
spinal cord barrier, endothelial damage, and hypoperfusion [6].
Furthermore, Crossbreeding SOD1
G93A mutant mice with mice
overexpressing VEGF in neurons produces a phenotype charac-
terized by delayed motoneuron loss and motor impairment, and
prolonged survival compared with mice carrying the SOD1
G93A
gene alone [7]. In addition, the cerebrospinal fluid VEGF levels
are significantly increased in patients with long duration of ALS
[8]. These findings suggest that chronic hypoxia have been
implicated in the pathology of ALS.
The human apj gene encodes a G protein-coupled receptor
(GPCR) [9]. Apelin was identified as an endogenous ligand for the
orphan GPCR APJ [10]. Apelin expression is high in human
spinal cord [11], and regulated by hypoxia [12], [13]. Recent
studies suggest that apelin protects neurons against glutamate-
induced excitotoxicity [14], [15]. Furthermore, we previously
showed that the apelin/APJ system cooperates with VEGF to
regulate vascular development in the retina [16]. Kidoya et al. also
demonstrated that apelin in combination with VEGF induced
proliferation and assembly of endothelial cells [17]. Therefore, the
apelin/APJ system alone or in combination with VEGF may play
a neuroprotective role in the pathogenesis of ALS. Here, to
examine whether apelin is an endogenous neuroprotective factor
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G93A mouse model of ALS, we have established
apelin deficient mice carrying the SOD1 mutation. In the present
study, we demonstrated that the apelin receptor APJ was detected
in neuronal cell bodies located in spinal cord, that apelin
expression in spinal cord of SOD1
G93A mice was reduced along
with the paralytic phenotype, and that apelin deficiency
accelerated the progression of ALS. In addition to in vivo studies
using transgenic mice, our in vitro studies showed that apelin
enhanced the protective effect of VEGF on oxidative stress-
induced neuronal death. Our findings suggest that apelin/APJ
system plays a protective role in the pathogenesis of ALS.
Results
Apelin and APJ expressions in mouse CNS tissues
We analyzed the precise distribution of apelin and APJ mRNA
in mouse CNS tissues by real-time RT-PCR method. As shown in
Fig. 1, the highest expression of apelin was observed in the spinal
cord (4-fold higher than olfactory bulb, Fig. 1A). APJ receptor
expression was also highest in the spinal cord (Fig. 1B).
To identify the target cells for apelin/APJ system in spinal cord,
we examined APJ expression in the spinal cord by immunohis-
tochemical staining. In the spinal cord from wild-type mice at 14
weeks of age, APJ-positive cells were located in the ventral horn
and around the central canal, which were colocalized with NeuN,
a neuronal marker, -positive cells throughout the spinal cord gray
matter (Fig. 2A–C). In contrast, APJ was expressed in neither glial
fibrillary acidic protein (GFAP)-positive glial cells Fig. 2D–F) nor
IbaI-positive microglia (data not shown) in spinal cord. In addition
that the APJ-positive cells were in the large neurons of ventral
horn, we addressed APJ was expressed in the choline acetyltans-
ferase (ChAT)-positive cells by immunostaining in adjacent
sections (data not shown). These data indicated that APJ was
expressed in the motor neurons.
Apelin mRNA expression is downregulated in spinal
cords of SOD1
G93A mice
The first clinical signs of motor neuron disease in SOD1
G93A
mice were fine hind limb tremors. The SOD1
G93A mice began to
display hind limb tremors around 10 weeks, gait abnormalities
around 14 weeks, and dragging of at least one hind limb around
18 weeks, whereas the control mice never showed signs of motor
dysfunction (Fig. 3A). Contrasted with the progressive weight gain
of the control group, body weight loss in SOD1
G93A mice became
evident around 10 weeks of age (Fig. 3B). Furthermore, we
investigated the number of motor neuron in the lumbar spinal
cord sections from 4-week-old to adult mice by ChAT immuno-
staining. Compared with control group, SOD1
G93A mice began to
show prominent depletion of anterior horn motor neurons around
14 weeks age (Fig. 3C).
We next compared the expressions of apelin and APJ mRNA in
lumbar spinal cord of SOD1
G93A mice with those of control mice
using real-time RT-PCR. In SOD1
G93A mice, apelin expression in
the spinal cord was significantly decreased at the 14 and 18 weeks
age (Fig. 4A). In contrast to spinal cord, apelin expression in the
lung of SOD1
G93A mice was similar to that of control mice at the
18 weeks age (Control: 1.0060.11, TG: 1.0060.12). On the other
hand, there was not a significant difference in APJ expression in
lumbar spinal cord of between control and SOD1
G93A mice
(Fig. 4B).
Apelin deficiency accelerates the progression of the
disease in SOD1
G93A mice
To evaluate the effects of apelin deficiency on the SOD1
G93A
neurodegenerative phenotype, we compared double mutant
apelin-KO and SOD1
G93A (KO-SOD1
G93A) mice with their
SOD1
G93A littermates in motor performance. We previously
reported that apelin-KO mice exhibited normal behavioral
phenotype other than ocular abnormality [16]. We also performed
the rotarod and footprint tests recording locomotion which
displayed comprised motor functions and gait disturbance of
mice. Consistent with our previous data [16], we could not detect
the abnormality of the motor performance in apelin-KO mice
with intact SOD1 (Fig. 5). On the other hand, KO-SOD1
G93A
mice displayed hindlimb tremors earlier than SOD1
G93A litter-
mates (Fig. 6A). In the rotarod test, SOD1
G93A littermates had a
learning phase showing improvement until 11 weeks of age,
sustained their maximal performance level, and began to decline
steadily at 14 weeks of age. In contrast to SOD1
G93A littermates,
KO-SOD1
G93A mice had a learning phase until 9 weeks of age
and subsequently performed significantly less well than SOD1
G93A
littermates (Fig. 6B). Moreover, we investigated the number of
motor neurons in lumbar spinal cord of KO-SOD1
G93A mice and
Figure 1. Apelin and APJ mRNA expression profiles in mouse
CNS tissues. Expression of apelin (A) and APJ (B) in wild type mice
were examined by real-time PCR (n=3–4). Data are expressed as
arbitrary units normalized to b-actin, and represent mean 6 SEM.
doi:10.1371/journal.pone.0023968.g001
Figure 2. APJ expression in the lumbar spinal cord of WT mice.
Representative pictures of ventral horn show double immunostaining
for APJ and NeuN (A–C) or GFAP (D–F) in the lumbar spinal cord. Scale
bar=200 mm (upper panels), 100 mm (lower panels).
doi:10.1371/journal.pone.0023968.g002
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G93A littermates at 14 weeks of age by ChAT immuno-
staining. The number of ChAT-positive neurons in KO-
SOD1
G93A mice was significantly decreased compared with
SOD1
G93A littermates (Fig. 6C).
Microglial activation contributes to the oxidative stress and
damage involved in the ALS process, and parallels the disease
progression [18]. Also, the expression of mutant SOD1 in
microglia contributes to the progression motor neuron degener-
ation [19], [20]. In fact, we detected that the microglia of
SOD1
G93A mice in lumber spinal cord were significantly activated
at 18 weeks of age (WT: 2.6460.22%, SOD1
G93A: 6.7562.16%).
Therefore, to evaluate the disease progression, we next examined
the microglia activation in lumbar spinal cord of KO-SOD1
G93A
mice and SOD1
G93A littermates at 14 weeks of age. The Iba1
+
microglial cell population in the lumbar spinal cord of KO-
SOD1
G93A mice was significantly increased two-fold compared
with SOD1
G93A littermates (Fig. 7). These data suggest that apelin
deficiency promotes the disease progression of SOD1
G93A mice.
Neuroprotective effect of apelin on cell death induced by
hydrogen peroxide in primary neurons
We next examined whether apelin protects neurons against cell
death. Consistent with previous report [14], we detected the
robustly expressed APJ in rat primary hippocampus neurons, not
cerebral cortex neurons, by RT-PCR (Fig. 8A). The cultured
hippocampal neurons were exposed to 10 mM hydrogen peroxide,
which is known to induce apoptosis for 24 hours, and then cell
death was measured 24 h later by 3- (4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazoilium bromide (MTT) assay. Apelin alone did
not affect on cell viability in the absence of hydrogen peroxide
(Fig. 8B). Moreover, Apelin alone (1–100 mM) did not protect
hydrogen peroxide-induced cell death (Fig. 8C). However,
100 mM apelin co-applied with VEGF (50 ng/ml) showed
significant neuroprotection (Fig. 8D).
Discussion
SOD1 mutants such as G93A lead to the blood-spinal cord
barrier breakdown and subsequent reduction in blood flow
through lumbar spinal cord [6], [21]. In VEGF
d/d mice exhibiting
ALS like phenotype, baseline neural blood flow was also lower
than that of control mice [5]. Chronic hypoxia has been linked to
motor neuronal death in ALS [1], [22]. In addition, apelin
expression was upregulated by hypoxia in astrocyte (data not
shown) as well as other cell types [12], [13]. Therefore, we
predicted that apelin expression would be upregulated in the
spinal cord of SOD1
G93A mice. Unexpectedly, we found that
apelin expression in spinal cord was declined along with the
progression of ALS. Mutant SOD1 including G93A disrupts the
RNA stabilization, possibly by altering the ribonucleoprotein
complex, and downregulates VEGF expression [23]. This
dysregulation is mediated through the adenylate/uridylate-rich
Figure 3. Time course of disease progression in SOD1
G93A mice monitored with three different tests. (A) Motor signs (hind limb tremors)
were measured with the clinical scoring system (see methods). (B) Body weight was monitored twice a week. (C) The number of ChAT-positive cell
bodies was decreased at end-stage disease for SOD1
G93A mice. **p,0.01 vs. wild-type mice. Data represent mean 6 SEM.
doi:10.1371/journal.pone.0023968.g003
Figure 4. Gene expression in lumbar spinal cord of SOD1
G93A
mice. Temporal expression patterns of apelin (A) and APJ (B) in the
lumbar spinal cord of wild-type (open column) and SOD1
G93A (closed
column) mice were examined by real-time RT-PCR (n=3–6). Data are
mean 6 SEM. **p,0.01 vs. wild-type mice.
doi:10.1371/journal.pone.0023968.g004
Figure 5. Motor performance in apelin-KO mice. (A) Rotarod test.
The average for time spend on the rotarod across five test trials for wild-
type (open circles, n=22) and apelin-KO (closed circles, n=22) mice. (B)
Footprint analysis of wild-type (open column, n=12) and apelin-KO
(closed column, n=14). The base of support was determined by
measuring the distance between the central pads of the hind paws
(DBF). The stride lengths of the hind paws (SL) were measured in two
consecutive prints. Data are mean 6 SEM.
doi:10.1371/journal.pone.0023968.g005
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where an aberrant ribonucleoprotein complex is formed in the
presence of mutant SOD1. In silico analysis, we found that the
apelin 39-UTR also have five AREs (unpublished). Accordingly,
the decline of apelin expression in spinal cord may be due to the
disruption of RNA stabilization by mutant SOD1.
The APJ expression was not changed in spite of a decrease in
ChAT neurons in the ALS mouse spinal cord, although the APJ
expressed in ChAT-positive neurons in the spinal cord. APJ is
expressed in not only ChAT-positive motor neurons but also
interneurons in the gray matter of the spinal cord (Fig. 2).
Therefore, the reason why we could not detect the decrease of APJ
expression may result from APJ abundantly expressed in other
neurons such as interneurons with the exception of motor neurons.
On the other words, apelin/APJ system may have not only the
neuroprotective effect, as suggested here, but also other roles such
as the regulation of reflex or nerve conduction. In fact, we detected
that the latency to lick the hind paw of apelin-KO mice was
significantly decreased that of wild-type mice using 55uC hot plate
test (wild-type: 26.361.31 s, apelin-KO: 22.161.56 s).
The distribution profiles were different from each other between
mRNA expression of apelin and APJ in murine brains, although
the highest expressions of apelin and APJ were observed in the
spinal cord (Fig. 1). One possibility is that apelin could additionally
act on receptors other than APJ in both the pons/medulla and the
midbrain with enrichment of white matter. Alternatively, APJ
could play a role other than apelin receptors in the cerebellum
with a lower expression of apelin.
Apelin which activates the PI3K/AKT signaling pathway
enhances angiogenesis induced by VEGF which also has a
neuroprotective effect through VEGFR-2/AKT signaling path-
way [16], [17]. Therefore, we examined whether apelin
significantly enhances the neuroprotective effect of VEGF
(Fig. 8). Apelin expectedly had a neuroprotective effect combined
with VEGF, although further study on the relation between the
apelin/APJ system and VEGF signaling is required. Meanwhile, a
previous report also shows that a low dose of apelin (1–5 nM)
significantly protects quinolinic acid-induced neuronal apoptosis in
mouse cortical neurons [15]. In this study, we could not detect the
neuroprotective effect of apelin alone (1–100 mM) against hydrogen
peroxide-induced neuronal death in rat hippocampal neurons, and
that was unexpected. The difference of neuroprotective effect
could be explained on the basis of experimental conditions used
such as treatment or species difference, or high doses of apelin
(1 mM). This induces not only the activation of cell survival
signaling such as ERK1/2 and AKT activation [24], [25], but also
AMP-activated protein kinase (AMPK) activation [26]. Therefore,
we cannot deny the possibility that the neuroprotective effect of
apelin could be masked by activating other signaling pathways.
Currently, existing treatment for ALS provides only marginal
benefit [27]. Insulin like growth factor-1 (IGF-1) is one of the most
promising factors as neurotrophic factors against ALS-related
Figure 6. Effect of apelin deficiency on disease progression of ALS mice. (A) Motor signs (hind limb tremors) were measured as in Fig. 3B. (B)
Rotarod performance of SOD1
G93A littermates (open circles) and KO-SOD1
G93A (closed circles) mice was measured as described in the methods for
180 s. (C) The number of motorneurons was decreased in the lumbar spinal cord of KO-SOD1
G93A mice at 14 weeks-old (n=3). Data represent mean
6 SEM. *p,0.05 vs. SOD1
G93A mice.
doi:10.1371/journal.pone.0023968.g006
Figure 7. Microglial activation in apelin deficient mice with mutant SOD1. Representative pictures show that Iba1-positive microglia in the
lumbar spinal cord of SOD1
G93A (A) and KO-SOD1
G93A (B) mice. (C) The Iba1-positive area was increased in the lumbar spinal cord of KO-SOD1
G93A
mice at 14 weeks-old (n=3). Scale bar=50 mm. *p,0.05 vs. SOD1
G93A. Data represent mean 6 SEM.
doi:10.1371/journal.pone.0023968.g007
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administration of IGF-1 had no significant effect on disease
progression of SOD1
G93A mice [29], and subcutaneous IGF-1 has
not shown benefit in 2-year ALS trial [30]. Furthermore, several
factors, including lithium and BDNF, also delay the disease
progression, but not completely protect the neuronal death in ALS
[31], [32]. These results indicate that it is difficult for single factor
to improve disease progression or survival of ALS. Our data that
apelin enhanced the neuroprotective effect of VEGF on oxidative
stress-induced neuronal death suggest a new cocktail therapy for
ALS.
In conclusion, this is the first experimental study addressing the
involvement of an endogenous apelin in the pathogenesis of ALS
by using SOD1
G93A mouse model, familial ALS model. Oxidized
species of wild-type SOD1 acquired 39-UTR binding and toxic
properties of ALS-linked mutant SOD1, implying that wild-type
SOD1 may be a contributor of pathogenesis in sporadic ALS [33].
Although further studies are required to determine the mecha-
nisms of apelin/APJ system in pathogenesis of ALS, impairment of
posttranscriptional processing of apelin RNA by mutant or
oxidized SOD1 may block an important neuroprotective pathway
and accelerates motor neuron degeneration.
Materials and Methods
Animals
Ethics Statement. The animal experiments were performed
in accordance with the guidelines of the Japanese Society for
Pharmacology and were approved by the Committee for the
Ethical Use of Experimental Animals at Setsunan University
(approval ID: K08-13/08.04.14.2.S.017). All efforts were made to
minimize animal suffering, reduce the number of animals used,
and utilize alternatives to in vivo techniques.
C57BL/6 mice with targeted disruption of the apelin gene
(apelin-KO) were generated as described previously [17]. Male
mice expressing SOD1
G93A (Jackson Laboratory #002726) was
backcrossed to C57BL/6 for at least 6 generations before the start
of the experimentation with the apelin-KO mice. We crossbred
male SOD1
G93A with female apelin
+/2 to assess the effect of
endogenous apelin deficient on motor performance in SOD1
G93A
mice. Apelin gene is located in chromosome X. Hence, all analyses
were performed with male littermates. Genotyping analysis was
performed in accordance with the Jackson Laboratory protocols
for SOD1
G93A mice and as previously described for apelin gene
[17]. These mice were housed in metallic breeding cages in a room
with a 12 h/12 h light/dark cycle. The humidity was 55%,
temperature was 23uC, and mice had free access to food and
water.
Quantitative PCR to measure transcription levels
Mice were euthanized and lumbar spinal cords were removed.
Total RNA extraction from lumbar spinal cord and reverse
transcription of total RNAs (1 mg) were performed as described
previously [34]. For gene expression analysis in cell culture, total
RNA extraction from primary neurons, and reverse transcription
of total RNAs (1 mg) were performed. Quantification of all gene
transcripts was conducted using quantitative real-time RT-PCR
with ABI Prism 7900-HT (Applied Biosystems; Foster City, CA).
Real-time RT-PCR was performed using SYBR premix Ex Taq II
(Takara, Ohtsu, Japan) with the use of primer pairs as previously
described [34].
Immunohistochemistry
Perfusion-fixed spinal cords were embedded in paraffin, and
serial transverse sections (3 mm) through the lumbar spinal cord
(L2–L4) were cut. Immunostaining for APJ, NeuN, GFAP,
activated microglia (IbaI), and ChAT was performed using rabbit
polyclonal anti-APJ as previously described [32], mouse mono-
clonal anti-neuronal nuclei (1:300, Millipore), mouse monoclonal
anti-GFAP (Progen), rabbit polyclonal anti-Iba1 (WAKO), and
rabbit polyclonal anti-ChAT (1:350, Millipore). Secondary
antibodies were Alexa 568-conjugated anti-rabbit IgG (Molecular
Probes), biotin-labeled anti-mouse IgG (1:200, Dako) and FITC-
conjugated streptavidin (1:200, BD Bioscience), or peroxidase-
conjugated anti-rabbit IgG (Nichirei) and Immpact DAB (Vector
Laboratories). Immunostained sections were photographed using a
fluorescence microscope (AZ-100M, Nikon, Japan). Preimmu-
nized rabbit immunoglobulins were used as a negative control to
confirm specific staining.
For the number of motor neurons, we counted the total number
of the ChAT-positive cell bodies in 8 sections of lumber spinal
cord (L2–4) selected every 100 mm. For quantification of
microglial activation, we measured the percentage of the area of
IbaI positive cells in the gray matter of lumber spinal cord (L2–
L4).
Behavioral test
Beginning at 7.5 weeks, all animals (n=10/genotype) were
weighed and evaluated for signs of motor deficit with the following
4 point scoring system twice a week (clinical score). 4 points if
normal, 3 points if hind limb tremors are evident when suspended
by the tail, 2 points if gait abnormalities are present, 1 point for
dragging of at least one hind limb, 0 points for inability to right
itself within 30 s.
Figure 8. Effect of apelin and VEGF on oxidative stress-induced
neurotoxicity in rat primary neurons. (A) Representative picture
shows the expression of APJ and apelin mRNA in primary cortical and
hippocampal neuronal cultures (representatively, C and H). Culture
medium was replaced with neurobasal media without B27 supplement
for 24 hours. (B) Cell viability of hippocampal neuronal cultures treated
with indicated concentration of apelin for 24 hours. The cultures were
treated with the indicated concentration of apelin (C) or with VEGF
(50 ng/ml) and apelin (indicated concentration) (D) for 15 min prior to
exposure to H2O2 (10 mM) for 24 hours. Cell viability was assessed by
MTT assay (n=4). *p,0.05 vs. control. Data represent mean 6 SEM.
doi:10.1371/journal.pone.0023968.g008
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time for which an animal could remain on the rotating cylinder of
a rotarod apparatus (Ugo Basile) at a constant speed of 12 rpm
was measured. Each animal was given three tries and the longest
latency to fall was recorded. 180 s was chosen as the arbitrary cut-
off time. For phenotype analysis of the apelin-KO mice with intact
SOD1, an accelerated rotarod was used. The apparatus has an
initially speed of 2 rpm and gradually accelerated at a rate of
0.11 rpm/s. Each animal was given five trials; interval time was
30 min; 300 s was chosen as a arbitrary cut-off time.
The footprint test was used to qualitatively compare the gait of
wild-type and apelin-KO mice. Footprint tests were performed at
8–12 weeks age of mice. To obtain footprints, the hind and
forefeet of the mice were coated with black nontoxic paints. The
animals were then allowed to walk along a 40-cm-long, 5-cm-wild
runway coated with a white paper. Each mouse had three trials.
Cell culture
Primary rat hippocampal cultures were prepared from embry-
onic day 17 Wister rat pups as previously described [35]. Cells
were plated at a density of 5610
5 cells/ml on culture dish pre-
coated with polyethylenimine and maintained in neurobasal media
with B27 supplement (Invitrogen) at 37uC/5% CO2 air, as
previously described [36]. After 8 days, the percentage of neurons
was assessed by counting the Microtubule-associated protein-2
(MAP-2) positive neurons, and then we could detect more than
95% neurons in primary neuronal culture.
Assessment of cell viability
Culture medium was replaced with neurobasal media without
the B27 supplement for 24 h. The cultures were treated with
apelin (Peptide institute Inc.) or with VEGF (Peprotech) and apelin
for 15 min prior to exposure to H2O2 for 24 h. Cell viability was
determined by the colorimetric MTT assay. After exposure to
H2O2, 0.5 mg/ml MTT was added and incubation carried out for
an additional 1 h. Then, 100 ml of dimethyl sulfoxide was added to
dissolve the formazan particles. Finally, absorbance at 570 nm was
measured with a microplate reader.
Statistical analysis
Statistical analysis of the experimental data was performed by
two-way analysis of variance followed by the Tukey–Kramer test
(Fig. 3, 4, 5, 6), Student’s t test (Fig. 6C), or one-way ANOVA
followed by the Dunnett’s test (Fig. 7, 8).
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